Clinical trials: Eosinophilic Asthma Patients
Asthma
Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller…
- Trial name
- PONENTE (NCT03557307)
- Testing
- Benralizumab
- Where
- 144 sites in United States, Argentina and 15 more
- Volunteers
- 598 people
- Sponsor
- AstraZeneca
Asthma; Eosinophilic
Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion
Unicentric prospective real life study designed to analyse the efficacy of Dupilumab to reduce bronchial inflammation of asthma measured by inflammatory cell counts obtained in induced sputum and other related characteristics…
- Trial name
- DEBORA (NCT05787678)
- Testing
- Dupilumab
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
add-on Maintenance Treatment of Patients With Severe Eosinophilic Asthma
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection
This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-5 Humanized Monoclonal Antibody injection in Healthy Subjects.
- Trial name
- NCT04445038
- Testing
- 610
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Asthma
Benralizumab Exacerbation Study
This is an exploratory study, the focus of which is to understand the nature of asthma exacerbations that occur despite open label benralizumab therapy in severe eosinophilic asthma.
- Trial name
- BenRex (NCT04102800)
- Testing
- Benralizumab
- Where
- 15 sites in United Kingdom
- Volunteers
- 157 people
- Sponsor
- NHS Greater Glasgow and Clyde
Severe Asthma
Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
The purpose of this cross-sectional, multicenter study is to determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients who attend to sites specialized in the…
- Trial name
- PREPARE (NCT03931954)
- Where
- 18 sites in Argentina, Chile and 4 more
- Volunteers
- 794 people
- Sponsor
- AstraZeneca
COPD Asthma, Eosinophilic Asthma
Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma
Around 1/3 of patients with COPD have elevated eosinophil levels. However, the role of eosinophils in COPD has not been yet understood and is probably different in COPD and in asthma.
- Trial name
- NCT05398133
- Where
- Poland
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Asthma
Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
Primary objective of the study is to evaluate whether patients with severe eosinophilic asthma who have received long-term treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to…
- Trial name
- NCT02555371
- Testing
- Mepolizumab 100mg
- Where
- 73 sites in United States, Argentina and 12 more
- Volunteers
- 306 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Asthma
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by…
- Trial name
- NCT01290887
- Testing
- Reslizumab
- Where
- 219 sites in United States, Argentina and 29 more
- Volunteers
- 1,052 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
Mepolizumab, a humanized monoclonal antibody, has been developed as an add-on treatment for subjects with severe asthma with eosinophilic inflammation.
- Trial name
- NCT03562195
- Testing
- Mepolizumab 100 milligrams, Salbutamol
- Where
- 42 sites in China
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Severe Eosinophilic Asthma
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to…
- Trial name
- STEP (NCT06465485)
- Testing
- Benralizumab
- Where
- 74 sites in China
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Severe Asthma
BRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS)
Asthma is a complex and heterogeneous disease. Severe asthma is recognised as a major unmet need that poses a great burden on the healthcare system.
- Trial name
- BRAEOS (NCT03925415)
- Where
- 6 sites in Brazil
- Volunteers
- 414 people
- Sponsor
- AstraZeneca
Eosinophilic Asthma
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of…
- Trial name
- BRISOTE (NCT06750289)
- Testing
- ICS-LABA, benralizumab
- Where
- 86 sites in United States, Bulgaria and 11 more
- Volunteers
- 130 people
- Sponsor
- AstraZeneca
Severe Asthma
Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients
This study aims to generate real-world data on the characteristics of patients receiving benralizumab to assess early PRO parameters as well as long-term treatment effects in the Gulf cooperative council (Kingdom of Saudi Arabia…
- Trial name
- iOUTRUN (NCT05603845)
- Where
- 24 sites in Colombia, Dominican Republic and 6 more
- Volunteers
- 291 people
- Sponsor
- AstraZeneca
Asthma; Eosinophilic, Asthma
Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma
A phase I clinical research study aimed at determining mechanisms that regulate airway mucosal inflammation in asthma endotypes using intranasal administration of endotoxin (lipopolysaccharide from E.
- Trial name
- Nasal-LPS (NCT06270576)
- Testing
- Lipopolysaccharides
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Eosinophilic Asthma Patients
A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients
The purpose of this study is to evaluation the long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients
- Trial name
- NCT06441812
- Testing
- SHR-1703 Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Asthma
Efficacy and Safety Study of 610 in Patients With Severe Asthma
The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.
- Trial name
- NCT06323213
- Testing
- 610
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Asthmatic Bronchitis
Gene Expression Profile and Inflammation Profile of Classic Asthma, Cough Variant Asthma and Eosinophilic Bronchitis
This study aims to identify and validate the gene expression differentials of peripheral blood mononuclear cells and differential inflammation profiles and other aspects in classic asthma, cough-variant asthma and eosinophilic…
- Trial name
- NCT02555345
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- State Key Laboratory of Respiratory Disease
Severe Eosinophilic Asthma
Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma
This study investigates the effect of removing eosinophils from peripheral blood (using treatment with Benralizumab, which is approved for the treatment of severe eosoniphilic asthma) on circulating dendritic cells in patients…
- Trial name
- NCT03652376
- Testing
- Benralizumab
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Rostock
Chronic Obstructive Pulmonary Disease
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma.
- Trial name
- SPEED (NCT06862206)
- Testing
- benralizumab
- Where
- 36 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Asthma, Eosinophilic Asthma
Intense Airway Eosinophilia in Asthma
In asthma, the type and importance of the inflammatory response in the airways has allows identification of different phenotypes.
- Trial name
- NCT03696914
- Where
- Canada
- Volunteers
- 918 people
- Sponsor
- Laval University